The negotiations on pharmaceutical IPRs are today in a state of a flux. The issues at stake are complex and fundamental and are likely to have a significant impact on the future and architecture of the system as a whole, both internationally and domestically. Multilateral discussions (and to some extent negotiations) over the future of pharmaceutical IPRs are taking place in various organizations, such as the WTO, the WHO, WIPO, OECD, UNCTAD, etc.
The workshop will consequently discuss the following emerging questions:
How can increased coordination of multilateral discussions lead to improvements in the system for pharmaceutical innovation, to address developed and developing country diseases and public health needs?
Are there any ways in which coordination between the various bodies can be enhanced?
What should be the role of external players in this process?
Will these negotiations lead to a better pharmaceutical IP system or will they damage it?